{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:57:17Z","timestamp":1779217037271,"version":"3.51.4"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have emerged as promising treatment strategies in cancer immunotherapy. However, a significant proportion of patients do not respond to these therapies, underscoring the need for reliable biomarkers of treatment responsiveness. Although a potential correlation between the development of immune-related adverse events (irAEs) and favorable response to ICI therapy has been demonstrated, the predictive reliability of irAEs for treatment efficacy remains to be fully established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>This report presents a case of advanced unknown primary carcinoma of the head and neck (UPCHN) with rapid disease progression following initial treatment with neck dissection and concurrent chemoradiotherapy. Subsequent administration of a weekly regimen comprising paclitaxel, carboplatin, and cetuximab (PCC) resulted in complete response (CR). Maintenance therapy with cetuximab and tislelizumab was then initiated. After 20 months of sustained CR, the patient developed grade 3 ICI-induced inflammatory arthritis (ICI-IA), necessitating discontinuation of ICI therapy. Notably, the patient remained in complete remission for over 1 year following cessation of ICI therapy, with no clinical or radiographic evidence of tumor progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that the development of ICI-IA reflects an immune hyperactivated state that correlates with long-term antitumor response to tislelizumab. The sustained remission observed in this patient following ICI discontinuation highlights the potential role of irAEs, particularly ICI-IA, as a potential biomarker of ICI efficacy. Further prospective, large-scale studies are warranted to validate these findings and assess their clinical applicability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1772943","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:45:06Z","timestamp":1776055506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoint inhibitor-induced inflammatory arthritis as a potential biomarker for long-term response to tislelizumab in advanced head and neck carcinoma: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaoqiong","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqiao","family":"He","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoning","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingna","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-0226","article-title":"DNA damage and repair biomarkers of immunotherapy response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015-0303-sa","article-title":"Non\u2013small cell lung cancer, PD-L1, and the pathologist","volume":"140","author":"Kerr","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/itt.s126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest","year":"2017","journal-title":"ITT"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2018.07.005","article-title":"M\u00e9canismes physiopathologiques des effets secondaires des immunoth\u00e9rapies par anticorps anti-CTLA-4, anti-PD-1 et anti-PD-L1 dans le traitement du cancer","volume":"105","author":"Passat","year":"2018","journal-title":"Bull du Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors \u2013 a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6507","DOI":"10.1200\/JCO.2020.38.15_suppl.6507","article-title":"TPExtreme randomized trial: Quality of life (QoL) and survival according to second-line treatments in patients with recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC)","volume":"38","author":"Guigay","year":"2020","journal-title":"JCO"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3849","article-title":"Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Chung","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00136-4","article-title":"Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial","volume":"22","author":"Sacco","year":"2021","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2025.102556","article-title":"Autoimmune-related adverse events induced by immune checkpoint inhibitors","volume":"94","author":"Sun","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093389","article-title":"Rheumatic manifestations in patients treated with immune checkpoint inhibitors","volume":"21","author":"Melissaropoulos","year":"2020","journal-title":"IJMS"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"JCO"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer\u2014clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheumatic Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez361","article-title":"An MRI study of immune checkpoint inhibitor\u2013induced musculoskeletal manifestations myofasciitis is the prominent imaging finding","volume":"59","author":"Daoussis","year":"2020","journal-title":"Rheumatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.05.002","article-title":"Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: fasciitis with myositis syndrome as a new complication of immunotherapy","volume":"17","author":"Narv\u00e1ez","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065643","article-title":"Rheumatic immune-related adverse events due to immune checkpoint inhibitors\u2014a 2023 update","volume":"24","author":"Dang","year":"2023","journal-title":"IJMS"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.40745","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single\u2010center cohort of sixty\u2010one patients","volume":"71","author":"Richter","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002511","article-title":"Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis","volume":"8","author":"Cappelli","year":"2022","journal-title":"RMD Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33780","article-title":"Immune\u2010related adverse events are associated with improved response, progression\u2010free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0390","article-title":"Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade","volume":"22","author":"Naidoo","year":"2017","journal-title":"Oncologist"},{"key":"B27","article-title":"Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0","volume":"34","author":"Woodworth","year":"2007","journal-title":"J Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.rdc.2016.09.007","article-title":"Immune-related adverse effects of cancer immunotherapy\u2014 implications for rheumatology","volume":"43","author":"Cappelli","year":"2017","journal-title":"Rheumatic Dis Clinics North America"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1772943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:45:16Z","timestamp":1776055516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1772943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1772943"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1772943","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1772943"}}